We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The response of Variant histology Bladder cancer to intravesical immunotherapy compared to conventional cancer.
- Authors
Gofrit, Ofer N.; Yutkin, Vladimir; Shapiro, Amos; Pizov, Galina; Zorn, Kevin C.; Hidas, Guy; Gielchinsky, Ilan; Duvdevani, Mordechai; Landau, Ezekiel H.; Pode, Dov
- Abstract
Background: High-grade urothelial carcinomas (UCs) often show foci of variant differentiation. There is limited information in the literature about the response of these variant urothelial tumors to immunotherapy with bacillus Calmette-Guerin (BCG). We compared the response, to treatment with BCG, of UC containing glandular, squamous, nested, and micropapillary types of differentiation to response of conventional non-muscle invasive high-grade UC. Methods: A total of 100 patients were diagnosed with variant histology urothelial cancer between June 1995 and December 2013. Forty-one patients with Ta or T1, confirmed by second look biopsies, received immunotherapy with BCG. Fourteen patients in this group were diagnosed with micropapillary differentiation, 13 patients with squamous differentiation, 9 patients with glandular differentiation, and 7 patients with nested variants. The control group included 140 patients with conventional high-grade UC. Both groups have been treated and followed similarly. Findings: Patients with variant tumors had similar clinical features to patients with conventional disease, including age, male to female ratio, stage, the presence of Tis, and median follow-up. Patients with variant tumors had a significantly worse prognosis compared to patients with conventional high-grade UC, including 5-year recurrence-free survival (63.5 Vs. 71.5%, p = 0.05), 5-year progression (⩾T2)-free survival (60 Vs. 82.5%, p = 0.002), 5-year disease-specific survival (73 Vs. 92.5%, p = 0.0004), and overall survival (66 Vs. 89.5%, 0.05). interpretation: A patient with variant bladder cancer treated with intravesical immunotherapy has a 27% chance of dying from this disease within 5 years compared to 7.5% chance for a patient with conventional high-grade UC.
- Subjects
TRANSITIONAL cell carcinoma; BLADDER cancer; IMMUNOTHERAPY; DIAGNOSIS
- Publication
Frontiers in Oncology, 2016, p1
- ISSN
2234-943X
- Publication type
Article
- DOI
10.3389/fonc.2016.00043